Amy Skorupa, MD
Hematology & Oncology · Chesapeake, VANPI 1780605576
Payments from drug & device makers
Across 122 payments — averaging $23.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$368
- AbbVie$292
- Sanofi$214
- Incyte Corporation$190
- Pfizer$181
- Johnson & Johnson$161
- plus $1K from 33 others
What the payments were for
- Food & beverage$2,78998%
- Education$492%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 16 | $368 |
| AbbVie(2 entities) | 9 | $292 |
| Sanofi | 10 | $214 |
| Incyte Corporation | 6 | $190 |
| Pfizer | 9 | $181 |
| Johnson & Johnson | 7 | $161 |
| Merck | 2 | $143 |
| Myriad Genetic Laboratories, Inc. | 1 | $110 |
| AstraZeneca | 5 | $102 |
| Daiichi Sankyo Inc. | 4 | $100 |
| E.r. Squibb & Sons, L.L.C. | 5 | $95 |
| Genentech USA, Inc. | 5 | $92 |
| Puma Biotechnology, Inc. | 4 | $71 |
| Lilly USA, LLC | 5 | $63 |
| GSK | 3 | $57 |
| Seagen Inc. | 3 | $51 |
| Array Biopharma Inc | 2 | $47 |
| Tersera Therapeutics LLC | 2 | $46 |
| Bristol Myers Squibb | 2 | $39 |
| Springworks Therapeutics, Inc. | 1 | $33 |
| Ipsen Biopharmaceuticals, Inc | 2 | $31 |
| Jazz Pharmaceuticals Inc. | 2 | $27 |
| Boehringer Ingelheim | 1 | $25 |
| Taiho Oncology, Inc. | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Partner Therapeutics, Inc. | 1 | $23 |
| Verastem, Inc. | 1 | $23 |
| Stemline Therapeutics Inc. | 1 | $22 |
| Tempus AI, Inc | 1 | $22 |
| Beone Medicines USA, Inc. | 1 | $21 |
| Immunocore Limited | 1 | $20 |
| Advanced Accelerator Applications | 1 | $18 |
| Tesaro, Inc. | 1 | $18 |
| Dova Pharmaceuticals | 1 | $18 |
| CSL Behring | 1 | $14 |
| Clovis Oncology, Inc. | 1 | $14 |
| Rigel Pharmaceuticals, Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KEYTRUDA$124
- PreciseTumor$110
- NATRELLE$107
How this compares
$2,838 in reported general payments places this provider in the 45th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 16 | $259,546 |
| RevlimidLenalidomide | 16 | $188,839 |
| VerzenioAbemaciclib | 11 | $158,348 |
| EliquisApixaban | 14 | $8,356 |
| Anastrozole | 251 | $5,622 |
| Exemestane | 15 | $2,113 |
| Ondansetron Hcl | 35 | $1,201 |
| Ibandronate Sodium | 22 | $684 |
| Letrozole | 58 | $675 |
| Dexamethasone | 18 | $660 |
| Prochlorperazine Maleate | 22 | $618 |
| Tamoxifen Citrate | 30 | $533 |
| Acyclovir | 16 | $302 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 18 | $183 |
| Potassium Chloride | 11 | $151 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $181 | $267,90130 claims |
| Bristol Myers SquibbRevlimid | $39 | $188,83916 claims |
| Lilly USA, LLCVerzenio | $63 | $158,34811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 293 hematology & oncology providers in Virginia.
Other hematology & oncology in Chesapeake
- William MaclaughlinChesapeake$268K
- Craig PortellCharlottesville$12.9M
- Amanda Gillespie-TwardyRoanoke$12.2M
- Sekwon JangFairfax$11.8M
- Mark FlemingHampton$10M
- Mark KochenderferRoanoke$8.6M
- Mitul GandhiManassas$6.9M
- Michael DansoNorfolk$6.9M
- Jerome GoldschmidtChristiansburg$6.5M
- William IrvinMidlothian$4.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.